AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India for the additional indication of Olaparib film-coated Tablets 100 mg & 150 mg (Lynparza).
Through this approval, Olaparib in combination with Durvalumab is indicated for the maintenance treatment of adult patients with advanced or recurrent endometrial cancer whose disease has not progressed on first-line treatment with Durvalumab in combination with platinum-based chemotherapy.
The receipt of this permission paves way for the launch of Olaparib film-coated Tablets 100 mg & 150 mg (Lynparza) in India for the above specified additional indication, subject to the receipt of related statutory approvals, if any.
Shares of AstraZeneca Pharma India Limited was last trading in BSE at Rs. 6463.15 as compared to the previous close of Rs. 6455.40. The total number of shares traded during the day was 2460 in over 790 trades.
The stock hit an intraday high of Rs. 6587.00 and intraday low of 6410.75. The net turnover during the day was Rs. 15985231.00. |
